With the in‐depth analysis of cellular and molecular immune responses in CML, including profiling of T cells specific to leukemia‐associated antigen PR1 with TCRβ‐sequencing, the authors identified the active NK cells and anti‐PR1 T cells that could help maintain TFR in pts discontinuing TKI treatment. Here, TMEM37 is linked to leukemia.